GlaxoSmithKline Pharmaceuticals Share Price Today (GLAXO)
TODAY IN ONE LINE
GLAXO fell 2.0% on light volume, lagging Nifty's 1.1% move.
With a market cap of ₹41,579.02 Cr., it trades at a P/E of 40.23. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
GlaxoSmithKline Pharmaceuticals flags
Key strengths and potential risks.
Green Flags
- ●High Capital EfficiencyROCE of 61.4% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 45.6%
- ●Healthy Operating MarginsOPM is structurally strong at 34.3%
- ●High Promoter HoldingPromoters hold 75.0% skin-in-the-game
- ●Steady Dividend YieldReliable 4.06% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
What changed recently?
Recent events, corporate actions, and announcements.
GlaxoSmithKline Pharmaceuticals Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for GlaxoSmithKline Pharmaceuticals Limited, framed against the sector median so the premium or discount is obvious at a glance.
GlaxoSmithKline Pharmaceuticals Limited trades at a P/E of 40.23× and P/B of 18.38×, against the Healthcare sector median P/E of 45.03×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
GlaxoSmithKline Pharmaceuticals Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for GlaxoSmithKline Pharmaceuticals Limited — derived from the live tape, not yesterday's close.
GlaxoSmithKline Pharmaceuticals Limited last traded at ₹2,454.8 with an intraday range of ₹2,430–₹2,510.6 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹2454.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2661.47 | +206.67 | +8.42% |
| R3 | 2580.87 | +126.07 | +5.14% |
| R2 | 2545.73 | +90.93 | +3.70% |
| R1 | 2500.27 | +45.47 | +1.85% |
| PIVOT | 2465.13 | 10.33 | 0.42% |
| CURRENT | 2454.80 | — | — |
| S1 | 2419.67 | -35.13 | -1.43% |
| S2 | 2384.53 | -70.27 | -2.86% |
| S3 | 2339.07 | -115.73 | -4.71% |
| S4 | 2258.47 | -196.33 | -8.00% |
GLAXO is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹2474.4–₹2510.6
Trading Below opening range, showing Bearishness
GlaxoSmithKline Pharmaceuticals Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for GlaxoSmithKline Pharmaceuticals Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
GlaxoSmithKline Pharmaceuticals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹41,579.02 Cr. and reported EPS of ₹61.23.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 3,749 | 3,822 ▲ 1.9% |
| Sales Growth YoY %Derived | 8.56% | 1.93% |
| Other Income | 146 | 145 ▼ 0.4% |
| Total Income | 3,895 | 3,967 ▲ 1.8% |
| 1,391 | 1,351 ▼ 2.9% | |
| Gross ProfitDerived | 2,358 | 2,471 ▲ 4.8% |
| Gross Margin %Derived | 62.90% | 64.65% |
| 1,181 | 1,161 ▼ 1.7% | |
| EBITDA (Operating Profit)Derived | 1,177 | 1,309 ▲ 11.2% |
| OPM %Derived | 31.40% | 34.26% |
| 73 | 90 ▲ 23.4% | |
| Profit Before Tax (PBT) | 1,260 | 1,406 ▲ 11.6% |
| 332 | 370 ▲ 11.4% | |
| Effective Tax %Derived | 26.38% | 26.32% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 928 | 1,036 ▲ 11.7% |
| Net Profit (Owner's PAT)Derived | 928 | 1,036 ▲ 11.7% |
| Net Profit Margin %Derived | 24.74% | 27.11% |
| PAT Growth YoY %Derived | 57.23% | 11.69% |
| Earnings Per Share (EPS ₹) | 54.75 | 61.15 ▲ 11.7% |
| Diluted Shares Outstanding (Cr) | 17 | 17 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -3 | -8 ▼ 183.5% |
| Total Expenses (incl. D&A & Interest) | 2,635 | 2,561 ▼ 2.8% |
| Material Cost % of RevenueDerived | 13.33% | 11.41% |
| Employee Cost % of RevenueDerived | 15.46% | 15.89% |
| Other Cost % of RevenueDerived | 16.04% | 14.50% |
| Interest Coverage (x)Derived | 847.76x | 455.22x |
| Period | Mar 2018 | Mar 2019 | Sept 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sept 2022 | Mar 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,896 | 3,128 ▲ 8.0% | 1,670 ▼ 46.6% | 3,224 ▲ 93.1% | 3,199 ▼ 0.8% | 3,278 ▲ 2.5% | 1,662 ▼ 49.3% | 3,252 ▲ 95.7% | 3,454 ▲ 6.2% | 1,825 ▼ 47.1% | 3,749 ▲ 105.4% | 3,822 ▲ 1.9% | |
| Sales Growth YoY %Derived | — | 8.03% | — | 3.08% | -0.79% | 2.47% | — | -0.80% | 6.21% | — | 8.56% | 1.93% | |
| Other Income | 55 | 102 ▲ 87.6% | 47 ▼ 54.4% | 79 ▲ 69.2% | 111 ▲ 40.0% | 76 ▼ 31.5% | 50 ▼ 34.6% | 101 ▲ 103.0% | 123 ▲ 21.8% | 70 ▼ 42.8% | 146 ▲ 107.9% | 145 ▼ 0.4% | |
| Total Income | 2,950 | 3,230 ▲ 9.5% | 1,717 ▼ 46.9% | 3,303 ▲ 92.4% | 3,309 ▲ 0.2% | 3,354 ▲ 1.3% | 1,712 ▼ 49.0% | 3,352 ▲ 95.9% | 3,576 ▲ 6.7% | 1,896 ▼ 47.0% | 3,895 ▲ 105.5% | 3,967 ▲ 1.8% | |
1,241 | 1,358 ▲ 9.4% | 701 ▼ 48.4% | 1,308 ▲ 86.7% | 1,313 ▲ 0.4% | 1,356 ▲ 3.3% | 652 ▼ 51.9% | 1,285 ▲ 97.1% | 1,335 ▲ 3.9% | 680 ▼ 49.1% | 1,391 ▲ 104.6% | 1,351 ▼ 2.9% | ||
| Gross ProfitDerived | 1,654 | 1,770 ▲ 7.0% | 969 ▼ 45.2% | 1,917 ▲ 97.7% | 1,886 ▼ 1.6% | 1,922 ▲ 1.9% | 1,010 ▼ 47.4% | 1,967 ▲ 94.7% | 2,119 ▲ 7.7% | 1,146 ▼ 45.9% | 2,358 ▲ 105.9% | 2,471 ▲ 4.8% | |
| Gross Margin %Derived | 57.13% | 56.59% | 58.04% | 59.44% | 58.96% | 58.63% | 60.77% | 60.49% | 61.36% | 62.76% | 62.90% | 64.65% | |
1,149 | 1,169 ▲ 1.8% | 610 ▼ 47.8% | 1,259 ▲ 106.4% | 1,191 ▼ 5.4% | 1,160 ▼ 2.6% | 604 ▼ 47.9% | 1,163 ▲ 92.4% | 1,210 ▲ 4.1% | 593 ▼ 51.0% | 1,181 ▲ 99.0% | 1,161 ▼ 1.7% | ||
| EBITDA (Operating Profit)Derived | 506 | 601 ▲ 18.8% | 359 ▼ 40.2% | 657 ▲ 82.9% | 695 ▲ 5.8% | 762 ▲ 9.6% | 406 ▼ 46.7% | 804 ▲ 98.2% | 909 ▲ 13.0% | 552 ▼ 39.2% | 1,177 ▲ 113.2% | 1,309 ▲ 11.2% | |
| OPM %Derived | 17.47% | 19.21% | 21.52% | 20.38% | 21.74% | 23.24% | 24.42% | 24.73% | 26.31% | 30.25% | 31.40% | 34.26% | |
56 | 78 ▲ 39.0% | 445 ▲ 471.4% | -252 ▼ 156.8% | -90 ▲ 64.4% | 82 ▲ 191.1% | 33 ▼ 59.3% | 67 ▲ 100.3% | -72 ▼ 208.3% | 39 ▲ 153.5% | 73 ▲ 88.6% | 90 ▲ 23.4% | ||
| Profit Before Tax (PBT) | 540 | 683 ▲ 26.4% | 764 ▲ 11.8% | 306 ▼ 60.0% | 551 ▲ 80.1% | 779 ▲ 41.5% | 422 ▼ 45.8% | 836 ▲ 98.1% | 816 ▼ 2.4% | 593 ▼ 27.3% | 1,260 ▲ 112.4% | 1,406 ▲ 11.6% | |
189 | 237 ▲ 25.4% | 147 ▼ 37.9% | 213 ▲ 44.4% | 192 ▼ 9.5% | 398 ▲ 107.1% | 113 ▼ 71.7% | 229 ▲ 103.3% | 226 ▼ 1.1% | 158 ▼ 30.0% | 332 ▲ 109.8% | 370 ▲ 11.4% | ||
| Effective Tax %Derived | 35.05% | 34.76% | 19.28% | 69.52% | 34.94% | 51.12% | 26.65% | 27.35% | 27.72% | 26.70% | 26.38% | 26.32% | |
| Profit/Loss from Discontinued Ops | — | — | — | — | — | 1,314 | 3 ▼ 99.8% | 3 ▲ 0.0% | — ▼ 100.0% | — | — | — | |
| Total Profit for Period | 351 | 445 ▲ 27.0% | 616 ▲ 38.4% | 93 ▼ 84.9% | 358 ▲ 284.3% | 381 ▲ 6.3% | 313 ▼ 17.9% | 611 ▲ 95.3% | 590 ▼ 3.4% | 435 ▼ 26.3% | 928 ▲ 113.3% | 1,036 ▲ 11.7% | |
| Net Profit (Owner's PAT)Derived | 351 | 445 ▲ 27.0% | 616 ▲ 38.4% | 93 ▼ 84.9% | 358 ▲ 284.3% | 381 ▲ 6.3% | 313 ▼ 17.9% | 611 ▲ 95.3% | 590 ▼ 3.4% | 435 ▼ 26.3% | 928 ▲ 113.3% | 1,036 ▲ 11.7% | |
| Net Profit Margin %Derived | 12.11% | 14.24% | 36.90% | 2.89% | 11.20% | 11.62% | 18.82% | 18.78% | 17.08% | 23.82% | 24.74% | 27.11% | |
| PAT Growth YoY %Derived | — | 26.99% | — | -79.07% | 284.28% | 6.32% | — | 60.38% | -3.39% | — | 57.23% | 11.69% | |
| Earnings Per Share (EPS ₹) | 20.70 | 26.29 ▲ 27.0% | 36.38 ▲ 38.4% | 5.50 ▼ 84.9% | 21.14 ▲ 284.4% | 100.04 ▲ 373.2% | 18.46 ▼ 81.5% | 36.05 ▲ 95.3% | 34.83 ▼ 3.4% | 25.67 ▼ 26.3% | 54.75 ▲ 113.3% | 61.15 ▲ 11.7% | |
| Diluted Shares Outstanding (Cr) | 17 | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 6 | -5 ▼ 198.2% | -2 ▲ 63.2% | -4 ▼ 96.9% | -2 ▲ 48.5% | -2 ▲ 9.8% | 4 ▲ 310.3% | -6 ▼ 255.3% | -4 ▲ 31.0% | — ▲ 100.0% | -3 | -8 ▼ 183.5% | |
| Total Expenses (incl. D&A & Interest) | 2,410 | 2,548 ▲ 5.7% | 1,354 ▼ 46.8% | 2,998 ▲ 121.3% | 2,759 ▼ 8.0% | 2,575 ▼ 6.7% | 1,289 ▼ 49.9% | 2,516 ▲ 95.1% | 2,760 ▲ 9.7% | 1,307 ▼ 52.6% | 2,635 ▲ 101.6% | 2,561 ▼ 2.8% | |
| Material Cost % of RevenueDerived | 17.64% | 21.95% | 15.78% | 14.71% | 14.76% | 18.64% | 17.23% | 13.15% | 15.79% | 15.73% | 13.33% | 11.41% | |
| Employee Cost % of RevenueDerived | 18.08% | 17.17% | 17.38% | 19.49% | 19.22% | 18.62% | 17.64% | 18.30% | 18.08% | 16.54% | 15.46% | 15.89% | |
| Other Cost % of RevenueDerived | 21.59% | 20.21% | 19.15% | 19.56% | 18.01% | 16.77% | 18.71% | 17.45% | 16.97% | 15.96% | 16.04% | 14.50% | |
| Interest Coverage (x)Derived | 2,462.21x | 1,004.00x | 171.64x | 90.69x | 174.52x | 346.85x | 349.22x | 408.02x | 466.12x | 810.91x | 847.76x | 455.22x |
GlaxoSmithKline Pharmaceuticals segment analysis : revenue and profit mix.
Disclosed business segments at GlaxoSmithKline Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
GlaxoSmithKline Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for GlaxoSmithKline Pharmaceuticals Limited.
Our AI distills the core fundamental drivers supporting GlaxoSmithKline Pharmaceuticals Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
GlaxoSmithKline Pharmaceuticals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
ROE 45.60% and ROCE 61.40% substantially exceed pharmaceutical peer averages consistently.
Operating margin 32.77% demonstrates exceptional pricing power and cost efficiency.
Net profit margin 27.21% ranks among highest in Indian pharmaceutical sector.
Negligible debt at ₹33.3 Cr with D/E ratio 0.0001 ensures financial fortress.
Promoter holding 75% signals strong long-term commitment and governance alignment.
Key Risks.
Latest quarterly EPS grew 5.70% YoY despite revenue headwinds, modest momentum.
Quarterly sales declined 1.16% YoY indicating near-term demand softness.
P/E ratio 39.69x elevated versus peer median, signals valuation premium.
Price-to-book 18.23x suggests limited margin of safety for new investors.
Payout ratio 161.76% exceeds earnings, unsustainable dividend structure long-term.
Flip Conditions.
Valuation risk. a P/E above 52 (~1.2× the sector multiple of 45.0) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 41% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 2.03%.
GlaxoSmithKline Pharmaceuticals Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — GlaxoSmithKline Pharmaceuticals Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
GlaxoSmithKline Pharmaceuticals Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for GlaxoSmithKline Pharmaceuticals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
GlaxoSmithKline Pharmaceuticals Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for GlaxoSmithKline Pharmaceuticals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in GlaxoSmithKline Pharmaceuticals Limited stood at 53.9% of traded volume, against a 20-day average of 56.0%.
GlaxoSmithKline Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings GlaxoSmithKline Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
GlaxoSmithKline Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 151 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Shareholders meeting
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on Jun 30, 2026. Further, the…
Trading Window
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider…
Action(s) taken or orders passed
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed
Updates
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Letter for weblink for Annual Report '.
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
GlaxoSmithKline Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue GlaxoSmithKline Pharmaceuticals has declared, sequenced by announce and record date.
GlaxoSmithKline Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About GlaxoSmithKline Pharmaceuticals Limited: business, sector, key facts.
What GlaxoSmithKline Pharmaceuticals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
GlaxoSmithKline Pharmaceuticals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GLAXO, BSE: 500660.
GlaxoSmithKline Pharmaceuticals Limited (GSK) is a major pharmaceutical company with a global presence, including significant operations in India. Its core business revolves around the manufacturing, distribution, and trading of a wide range of pharmaceutical products. The company's history stretches back to 1924, with its current name adopted in 2001. GSK's headquarters are located in Mumbai, India.
A substantial portion of GSK's business focuses on vaccines. Their portfolio includes Infanrix Hexa (for multiple infant diseases), Synflorix (pneumococcal diseases), Havrix (Hepatitis A), Menveo (meningococcal disease), Boostrix (diphtheria, tetanus, and pertussis), Fluarix Tetra (influenza), Varilrix (varicella), and Shingrix (herpes zoster). This extensive vaccine range caters to various age groups and disease preventions, establishing GSK as a key player in the global vaccine market.
Beyond vaccines, GSK offers a diverse portfolio of specialty medicines. Key examples include NUCALA, used to treat severe eosinophilic conditions like asthma, and TRELEGY ELLIPTA, a treatment for chronic obstructive pulmonary disease (COPD). These specialty medications target specific, often chronic, conditions, reflecting GSK's commitment to developing advanced therapies.
GSK also provides a broad selection of general medicines. This includes antibiotics like AUGMENTIN and CEFTUM for bacterial infections, various formulations for mineral and vitamin deficiencies (CobadexCZS, CCM), pain relievers (CALPOL), treatments for hypothyroidism (ELTROXIN), skin creams and ointments (Flutivate, Tenovate, BETNOVATE, PHYSIOGEL, NEOSPORIN, T-BACT) addressing a wide range of dermatological needs. This segment underscores GSK's commitment to providing accessible and widely used treatments for common ailments.
In summary, GlaxoSmithKline Pharmaceuticals Limited operates across multiple sectors of the pharmaceutical industry, offering a comprehensive range of vaccines, specialty medicines targeting complex conditions, and a large selection of general medicines for everyday health concerns. This diversified approach positions GSK as a significant player in the global pharmaceutical market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about GlaxoSmithKline Pharmaceuticals Limited (GLAXO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of GlaxoSmithKline Pharmaceuticals Limited (GLAXO)?
The current share price of GlaxoSmithKline Pharmaceuticals Limited (GLAXO) is ₹2,454.8. Today, the stock has declined by ₹51.50 (2.05%), trading in a range of ₹2,430 to ₹2,510.6. The stock opened at ₹2,506.3 with a trading volume of 56,156 shares.
02Is GlaxoSmithKline Pharmaceuticals Limited stock a good investment for long-term?
GlaxoSmithKline Pharmaceuticals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹41,579.02 crores, P/E ratio of 40.23, ROE of 45.60%, and ROCE of 61.40%. The dividend yield stands at 4.06%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of GlaxoSmithKline Pharmaceuticals Limited stock?
The 52-week high price of GlaxoSmithKline Pharmaceuticals Limited (GLAXO) is ₹3,220, while the 52-week low is ₹2,088.1. Currently trading at ₹2,454.8, the stock is 32.4% away from its 52-week low and 23.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy GlaxoSmithKline Pharmaceuticals Limited stock at the current price?
Whether to buy GlaxoSmithKline Pharmaceuticals Limited stock at ₹2,454.8 depends on multiple factors. The stock is currently trading with a P/E ratio of 40.23 and P/B ratio of 18.38. Today's performance shows a loss of 2.05%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of GlaxoSmithKline Pharmaceuticals Limited and when is the next dividend?
GlaxoSmithKline Pharmaceuticals Limited offers a dividend yield of 4.06%, which means for every ₹100 invested at the current price of ₹2,454.8, you can expect to receive approximately ₹4.06 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of GlaxoSmithKline Pharmaceuticals Limited?
GlaxoSmithKline Pharmaceuticals Limited's key financial metrics include: P/E Ratio: 40.23, P/B Ratio: 18.38, ROE: 45.60%, ROCE: 61.40%, Dividend Yield: 4.06%, EPS: ₹61.23, Book Value: ₹133.85, and Debt-to-Equity: 0.01. The company's market cap stands at ₹41,579.02 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is GlaxoSmithKline Pharmaceuticals Limited stock performing today in the market?
GlaxoSmithKline Pharmaceuticals Limited stock opened at ₹2,506.3 and is currently trading at ₹2,454.8, showing a decline of ₹51.50 (2.05%). The intraday high is ₹2,510.6 and low is ₹2,430. The trading volume stands at 56,156 shares, indicating moderate market participation today.
08What is the P/E ratio of GlaxoSmithKline Pharmaceuticals Limited and what does it indicate?
GlaxoSmithKline Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 40.23, which means investors are willing to pay ₹40.23 for every ₹1 of earnings. With an EPS of ₹61.23, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about GlaxoSmithKline Pharmaceuticals Limited (GLAXO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.